Although pending further investigation, it is also possible that the expression of distinct variants of the receptor at rs1801725 may lead to distinct CaSR signaling and/or tumor progression patterns in specific subtypes of highly heterogeneous cancers such as breast cancer. This evidence concerns the gene CASR and breast carcinoma.